Company profile: Exicure
1.1 - Company Overview
Company description
- Provider of a new class of immunomodulatory and gene silencing drugs against validated targets.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Exicure
Egen
HQ: United States
Website
- Description: Provider of safe, efficient delivery systems for the manufacture of nucleic acid and anti-cancer drugs and for creating products to treat human diseases, offering synthetic biocompatible delivery vehicles to deliver therapeutic genes, inhibitory RNA (siRNA & shRNA), and small molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Egen company profile →
Skyhawk Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapeutics and RNA-targeting platforms that correct RNA expression. Offers SKYSTAR for RNA target assessment and prioritization; SKYLIBRARY of RNA-targeting compounds; SKYSEQ multiplex screening for testing multiple RNA targets; and SKYAI machine-learning tools for advancing RNA splicing modulators. Pipeline includes SKY-0515, a small molecule RNA splicing modifier for Huntington’s disease in clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Skyhawk Therapeutics company profile →
Mirus Bio
HQ: United States
Website
- Description: Provider of nucleic acid-based technologies and gene transfer methods for the pharmaceutical business, including a proprietary RNAi delivery platform and tools for gene expression and biotherapeutic protein. Products include TransIT-VirusGEN for AAV/lentivirus vector production in research and clinical applications, RevIT AAV Enhancer, TransIT-LT1 transfection reagent, and GMP-grade ancillary materials for cell and gene therapy manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirus Bio company profile →
Spark Therapeutics
HQ: United States
Website
- Description: Provider of potentially curative, one-time gene therapy treatments for genetic diseases, including investigational programs such as SPK-8011 for hemophilia A, fidanacogene elaparvovec (SPK-9001) for hemophilia B, SPK-3006 for Pompe disease, and gene therapies targeting Stargardt and Huntington’s diseases, plus AAV-based research programs for the retina, liver, and central nervous system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spark Therapeutics company profile →
Generation Bio
HQ: United States
Website
- Description: Provider of genetic medicines including iqDNA, a DNA construct designed to carry large or multiple genes to cells, potentially treating a wide range of diseases; ctLNP, a cell-targeted lipid nanoparticle delivery system for specific tissue targeting enabling personalized, redosable treatments; and RES, a rapid enzymatic synthesis process that efficiently produces highly pure DNA constructs, aiming for global access to genetic medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Generation Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Exicure
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Exicure
2.2 - Growth funds investing in similar companies to Exicure
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Exicure
4.2 - Public trading comparable groups for Exicure
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →